TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05984264
Drug: lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.
Study: NCT04995653
Drug: Vancomycin Pre-Treatment
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four times daily dosing with Vancomycin
Study: NCT04995653
Drug: Vancomycin Placebo
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four times daily dosing with Vancomycin Placebo
Study: NCT04995653
Drug: SER-155
Normalized name: Ser
DrugBank: Serine (DB00133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily dosing with SER-155
Study: NCT06225323
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours.
Study: NCT05845567
Drug: Givinostat
Normalized name: givinostat
DrugBank: Givinostat (DB12645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
Study: NCT06023875
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
Study: NCT06023875
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
Study: NCT06023875
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
Study: NCT00000864
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000864
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06664320
Drug: hydroxyethyl starch (HES 130/0.6)
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyethyl starch (HES 130/0.6)
Study: NCT05197088
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of tamsulosin
Study: NCT06630585
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.~In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks.
Study: NCT06602271
Drug: Oxycodone HCl 10 mg
Normalized name: oxyCODONE HCl 10 MG Oral Tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator
Study: NCT05718323
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
Study: NCT04913337
Drug: NGM707 plus pembrolizumab (KEYTRUDA®)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
Study: NCT05236894
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given lower dose nicotine pouch
Study: NCT05236894
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given higher dose nicotine pouch
Study: NCT05236894
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given 3mg nicotine pouch (Aim 2)
Study: NCT04933916
Drug: EMB-001
Normalized name: EMB
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination product metyrapone and oxazepam
Study: NCT06579937
Drug: Esketamine hydrochloride
Normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: During anesthesia induction, a 0.2 mg/kg esketamine bolus was administered intravenously.
Study: NCT06315478
Drug: Omeprazole 20 MG Oral Tablet
Normalized name: omeprazole 20 MG Oral Tablet
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard triple therapy for 14 days Bid for each drug
Study: NCT06315478
Drug: Amoxicillin 500Mg Tab
Normalized name: AMOXICILLIN 500MG TAB
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quadruple regimen for 14 days Bid for each drug
Study: NCT06393257
Drug: Anti-infective therapy
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics were used in these patients.
Study: NCT04889157
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
Study: NCT05148403
Drug: glibenclamide
Normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide was given orally or by nasal feeding
Study: NCT04038619
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06683053
Drug: empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparing the benefits of both doses of empagliflozin (10 mg versus 25 mg) in terms of heart ejection fraction and quality of life.
Study: NCT06080880
Drug: Ondansetron every 3 weeks
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
Study: NCT06080880
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aprepitant, Po, 125mg/d, 1day' application every 3 weeks
Study: NCT06080880
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
Study: NCT06080880
Drug: Ondansetron weekly
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron, Po, 24mg/d, 3 days' application weekly
Study: NCT05881213
Drug: CKD-378 (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Quaque day (QD), PO
Study: NCT06623929
Drug: Etofenamat
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
Study: NCT05658055
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Potassium-competitive acid blocker
Study: NCT05658055
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for H. pylori eradication
Study: NCT00000892
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000892
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000892
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000892
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000892
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06509451
Drug: Giomer pit and fissure sealant without etching
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S-PRG filler containig pit and fissure sealant without etching step
Study: NCT06181305
Drug: letrozole 2,5 mg tablet
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mild ovarian stimulation
Study: NCT05017454
Drug: the optimized sodium valproate-loaded nanospanlastic dispersion
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
Study: NCT05017454
Drug: mometasone furoate lotion
Normalized name: mometasone furoate Topical Lotion
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
Study: NCT06508762
Drug: VX-993
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet and Suspension for Oral Administration.
Study: NCT05850468
Drug: lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative non opioid infusion in experimental group
Study: NCT06561360
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.
Study: NCT06561360
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.
Study: NCT06561360
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine IV on days 1-5 concurrently with rituximab.
Study: NCT06561360
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab on days 1-5 concurrently with rituximab.
Study: NCT06240351
Drug: Baricitinib 4 MG Oral Tablet
Normalized name: Baricitinib 4 mg oral tablet
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib is a Janus kinase (JAK) inhibitor
Study: NCT04926844
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
Study: NCT04926844
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
Study: NCT05919992
Drug: Metyrapone 250 mg Oral Tablets
Normalized name: metyrapone 250 MG
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During one phase of the study: Metyrapone (pills of 250mg) on empty stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
Study: NCT04567511
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bispecific monoclonal antibody binding to activated Factor IX and Factor X
Study: NCT06621680
Drug: Multivitamins
Normalized name: MULTIVITAMINS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
Study: NCT04896632
Drug: INE 963
Normalized name: INS 316
DrugBank: INS 316 (DB05390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days
Study: NCT06547424
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days
Study: NCT05918419
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody
Study: NCT06620354
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients without indications for surgical excision were evaluated with 6 cycles of daily oral smetinib capsules (20-50mg bid) for 30 days, individually calculated based on patient body surface area (BSA)
Study: NCT05376839
Drug: Cedirogant
Normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral
Study: NCT05613608
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
Study: NCT04902703
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
Study: NCT05930028
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 8 weeks.
Study: NCT05930028
Drug: Ezetimibe/Atorvastatin
Normalized name: ezetimibe/atorvastatin calcium 10 mg-10 mg ORAL TABLET
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects take the investigational products once a day for 8 weeks.
Study: NCT05930028
Drug: Ezetimibe/Atorvastatin Placebo
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects take the investigational products once a day for 8 weeks.
Study: NCT04233047
Drug: Fostemsavir
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
Study: NCT04921527
Drug: chiauranib
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg orally once daily
Study: NCT04921527
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
Study: NCT06621082
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles
Study: NCT05960227
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
Study: NCT04807504
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients receive erector spinae plane blocks with ropivacaine.
Study: NCT06617936
Drug: Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, 17 cycles at most. Recombinant Human Endostatin Injection (Endostar):210mg was pumped intravenously for 3 consecutive days, every 21 days for 1 cycle,17 cycles at most.
Study: NCT05285566
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
Study: NCT05285566
Drug: Xylocaine
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
Study: NCT06622603
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
Study: NCT06605222
Drug: SHR-7787 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
Study: NCT04917458
Drug: Cholecalciferol 4000 IU Oral Capsule, Liquid Filled
Normalized name: Cholecalciferol 4000 IU Oral Capsule, Liquid Filled
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.
Study: NCT06360978
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.
Study: NCT05208294
Drug: Sulpiride 400 MG
Normalized name: sulpiride 400 MG
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
Study: NCT06143124
Drug: Bismuth Subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
Study: NCT04892212
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The daily dose of sirolimus is divided twice.
Study: NCT06506019
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg psilocybin
Study: NCT05343364
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral Tablet
Study: NCT06212271
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description.
Study: NCT05212701
Drug: Reparixin
Normalized name: Reparixin
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
Study: NCT03673748
Drug: Mesenchymal stem cells (MSC)
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous injection of MSV in saline solution
Study: NCT06204107
Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once
Study: NCT05688605
Drug: MRG003+HX008
Normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04908215
Drug: INM-755 (cannabinol) cream
Normalized name: Inmazeb
DrugBank: Atoltivimab (DB15898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical cream containing cannabinol for dermal application